Analysis of polyvinyl alcohol release from commercially available daily disposable contact lenses using an in vitro eye model

Chau-Minh Phan, PhD, MSc ©,1 Hendrik Walther, PhD, MSc, BSc (Optom),1 Donald Riederer, PhD,2 Charis Lau, PharmD, OD, FAAO,2 Kathrine Osborn Lorenz, OD MS FAAO, FBCLA,2 Lakshman Nagapatnam Subbaraman, PhD, BSOptom, MSc, FAAO,1 Lyndon Jones, PhD, FCOptom, FAAO1

1Centre for Ocular Research & Education (CORE) – formerly Centre for Contact Lens Research (CCLR), School of Optometry and Vision Science, University of Waterloo, Waterloo, Ontario, N2L 3G1, Canada
2Johnson & Johnson Vision, Inc, Jacksonville, Florida

Received 13 June 2018; revised 10 September 2018; accepted 23 September 2018
Published online 16 October 2018 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/jbm.b.34259

Abstract: The purpose of this work was to determine the release of polyvinyl alcohol (PVA) from etafilcon A, omafilcon A, and neofilcon A daily disposable hydrogel contact lenses using a novel in vitro model. PVA is an ocular lubricant that can be found in multiple formulations of artificial tears. Neofilcon A innately contains PVA, so only the release of PVA from this lens was evaluated. Etafilcon A and omafilcon A lenses were incubated in a PBS solution containing PVA. The release of PVA was evaluated using a novel in vitro blink platform with Milli-Q water and PBS under various blink conditions and flow rates. Neofilcon A lenses significantly released more PVA than other lenses at 0.5 and 1.5 h in both PBS and Milli-Q water (p < 0.001). For neofilcon A, there was no statistical significance between the release profiles of PVA between the blink and no-blink conditions, or for the various flow rates (p > 0.05). All tested groups and lenses showed a burst release within the first 4.5 h and rapidly plateaued thereafter. The current study demonstrates that releasable PVA (whether through uptake or through being inherently available from the material) is loosely bound on hydrogel lenses, and the major- ity is released within 4.5 h. © 2018 The Authors. Journal of Biomedical Materials Research Part B: Applied Biomaterials published by Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater 107B:1662–1668, 2019.

Key Words: PVA, polyvinyl alcohol, contact lenses, uptake, release

How to cite this article: Phan C-M, Walther H, Riederer D, Lau C, Lorenz KO, Subbaraman LN, Jones L. 2019. Analysis of polyvinyl alcohol release from commercially available daily disposable contact lenses using an in vitro eye model. J Biomed Mater Res Part B 2019:107B:1662–1668.

INTRODUCTION
Contact lenses (CLs) are one of the most successful biomedical devices, with an estimated 140 million wearers worldwide.1 Despite their success, cessation of CL wear remains a pressing concern, with dropout rates being approximately 16% in the United States and as high as 30% in Europe and Asia.2 A primary reason for CL dropout remains discomfort with the lenses, particularly toward the end of the day.1–5 Not surprisingly, there has been a significant push in CL research to develop solutions to reduce CL discomfort (CLD).6

Although there are various approaches to tackle the problem of CLD, one that has relatively recently emerged relates to the release of “comfort” or wetting agents over time from the CL material into the tear film.7–14 Although several of these studies report the release of agents from theoretical “drug-delivery” materials,11–14 the release of polyvinyl alcohol (PVA), a wetting agent, has been reported from the commercially available daily disposable CLs material neofilcon A (Dailies Aqua Comfort Plus [DACP]).7–10,15,16 According to the manufacturer (Alcon, Fort Worth, TX), PVA is slowly released from the CL throughout the day through a blink-activated mechanism to improve end-of-day comfort.10

The concept of a drug delivering CL material that can slowly release wetting agents, like PVA, could also be applied to develop other CL materials to address CLD. However, to-date, there are a very limited number of studies that have experimentally examined the release kinetics of PVA from neofilcon A.8,10,15 There are two key challenges with regards to studying the release of PVA from CLs. The first problem is finding a suitable analytical assay that has a high sensitivity...
and selectivity for detection of PVA, as PVA does not contain a UV chromophore, so a straightforward spectrophotometric detection is not possible.17 The detection of PVA from the nelfilcon A material was previously achieved by measuring the RI (refractive index) of the solution.10 However, while RI is considered to be very sensitive, it is also nonspecific. An alternative colorimetric method for detecting PVA using iodine and borate has been previously published for PVA detection in waste water samples.18 This method produces a dark blue color change in the presence of PVA, which can be monitored at 630 nm, with a high degree of sensitivity and specificity.18

The second analytical problem is to develop an appropriate in vitro model capable of simulating the blink, as PVA release from nelfilcon A is reportedly dependent on a blink-activated mechanism.10 The action of the eyelid “squeezes” the lens and produces the necessary force to transport the PVA into the tear film.10 In addition, the model also ideally needs to simulate physiological tear volume (7 ± 2 μL)19 and tear flow (0.95–1.55 μL/min) 20 to correctly simulate physiological conditions on the ocular surface. Our laboratory has previously developed an in vitro eye model (OcuFlow) that is able to test CLs under conditions of physiological tear flow, tear volume, and a blink-actuated mechanism that mimics the action of blinking and air exposure. In addition, it also allows any elute from the CL to be captured and subsequently analyzed.21–24

The aim of the current study was to measure the release of PVA from nelfilcon A, and the uptake and release of PVA from two other commercially available hydrogel daily disposable CL materials, using the OcuFlow platform.

MATERIALS AND METHODS

CLs and lens preparation

The lenses tested in the current study were 1-Day Acuvue Moist (etafilon A, Johnson & Johnson, Jacksonville, FL), Proclear 1 Day (omafilon A, CooperVision Pleasanton, CA), and Dailies AquaComfort Plus (nelfilcon A, Alcon, Fort Worth, TX). Table I details the reported properties of the three CLs materials examined in the current study. As can be noted, the nelfilcon A material is the only one that contains PVA. The etafilon A and omafilon A lenses were loaded with PVA before extraction as described below, such that the release of PVA from these materials could be compared to nelfilcon A. All lenses were obtained in their original packaging with a dioptic power of −3.00 and base curve of 8.6 mm. The blister pack solution of etafilon A and omafilon A were used as negative controls, and the blister pack for nelfilcon A was used as a positive control for PVA.

Reagents

Polyvinyl alcohol (PVA) MW of 13–23 kDa (average MW = 18 kDa), iodine, phosphate buffered saline (PBS), and boric acid were purchased from Sigma-Aldrich (St. Louis, MO).

PVA incubation

To compare the release of PVA from nelfilcon A, the etafilon A and omafilon A lenses were soaked in a solution of PVA to model the uptake and release of PVA from these materials. Etafilcon A and omafilon A lenses were removed from the blister pack and soaked in 5 mL of PBS solution for 24 h to remove any blister pack components. These lenses were then incubated in 1 mL of PBS solution containing 1.8 mg/mL of PVA for 24 h on an orbital shaker at room temperature to “load” the lenses with PVA.

OcuFlow set-up

The set-up for the in vitro blink platform (OcuFlow) is shown in Figure 1. The standard flow rate for the current study was set to 6.9 μL/min (10 mL/day). This input flow rate translates to approximately 3.45 μL/min (5 mL/day) of collectable elute when accounting for evaporation under our laboratory conditions. This flow rate allows enough sample to be collected (100 μL/30 min) for analysis, which was collected using a 12-well plate. The collection time interval points were as follows: 0–0.5, 1–1.5, 4–4.5, 8–8.5, 12–12.5, and 23–23.5 h (n = 6 for each time point). The cycle for air exposure and mechanical rubbing (to simulate blinking) on the OcuFlow was set to 6.5 times/min. The spacing between the eyeball and eyelid pieces is approximately 250 μm.

Detection of PVA using iodine-borate assay

The following iodine-borate assay procedure was adopted from Prochazkova et al.18 The color reaction of PVA was performed under laboratory conditions at 22–26 °C. A volume of 0.100 mL of sample was added to 0.375 mL of boric acid (40 g/L) and 0.075 mL of iodine solution (25 g KI and 12.7 g I2 in 1 L of Milli-Q water). The sample was allowed to

---

**TABLE I. Properties of Daily Disposable Contact Lenses Used in the Study**

|                     | 1-Day Acuvue Moist | Proclear 1 Day | Dailies AquaComfort Plus |
|---------------------|--------------------|----------------|--------------------------|
| **USAN**            | etafilon A         | omafilon A     | nelfilcon A              |
| **Manufacturer**    | Johnson & Johnson  | CooperVision   | Alcon                    |
| **Water content (%)** | 58                 | 60             | 69                       |
| **FDA group**       | IV                 | II             | II                       |
| **Center thickness (mm)** | 0.08              | 0.09           | 0.10                     |
| **Oxygen permeability (x10−11)** | 28                | 33             | 26                       |
| **Principal components** | HEMA, PVP, MA     | HEMA, PC       | PVA, HPMC, PEG, FMA      |

FMA, N-formylmethyl acrylamide; HEMA, hydroxyethyl methacrylate; HPMC, hydroxypropylmethylcellulose; MA, methacrylic acid; NVP, N-vinyl pyrrolidone; PC, 2-methacryloxyethyl phosphorylcholine; PEG, polyethylene glycol; PVA, polyvinyl alcohol; PVP, polyvinyl pyrrolidone.
develop a color change for 20 min, and the absorbance of the 200 μL of sample was measured at 630 nm using a SpectraMax M5 UV-Vis Spectrophotometer (Molecular Devices, Sunnyvale, CA). Standard curves for PVA MW = 18 kDa were prepared from a stock concentration of 50 nmoL/mL in PBS and water, and then serially diluted to concentrations of 25, 12.5, 6.25, 3.125, and 1.5625 nmol/mL. The standard curves were used to calculate the concentration of PVA in the samples (n = 6).

In the current study, PVA was detected using an iodine-borate colorimetric assay. The assay was able to detect PVA in the blister pack and in the CL elute with a high degree of sensitivity and specificity. As shown in Figure 2, only the nefficon A lenses containing PVA turned a dark green-black color, indicative of the presence of PVA. This observed color change of PVA with iodine, from orange to green-black color, was the color change of PVA with iodine-borate, indicative of the presence of PVA. This color change is indicative for the presence of PVA.

Extraction of PVA from lenses

Six lenses of each type were placed in 1 mL of methanol contained in 2 mL vials (n = 6). The vials were capped, covered with parafilm, and placed on an orbital shaker. After 48 h, the lenses were removed and the sample was dried down using nitrogen gas. The sample was then reconstituted in 400 μL of Milli-Q water. For nefficon A lenses, the same methanol extraction procedure was also run for 1 min, and 24 h.

PVA release in MilliQ and PBS

Six lenses of each type were submerged in a rinsing solution for 1 s before mounted on the OcuFlow. The experiment was run as described in the OcuFlow section. About 100 μL of elute was collected from the wells at the specified time intervals and analyzed using the iodine-borate assay. One set of experiments was conducted with PBS, as the flow-through fluid and rinsing solution, and another set was conducted using Milli-Q water. This was undertaken as it was considered possible that the PBS and Milli-Q water flowing over the lenses may have differential impacts on lens swelling for the three lens materials. This would likely impact the release of the PVA and was considered an essential step to ensure that the lens ionicity did not impact the release rates.

PVA release from nefficon A for no-blink and low flow rate

The release of PVA from the nefficon A lenses has been described as being driven by the blink. To examine this, the following experiments were only conducted for nefficon A to examine the effects of blinking and a low flow rate on the release of PVA. Both experiments were conducted using PBS as the flow-through fluid. Six nefficon A lenses were submerged in a rinsing solution of PBS for 1 s and tested in the no-blink condition at the regular flow rate. For the no-blink condition, the OcuFlow was set to the closed position with no mechanical actuation.

For the low flow rate condition, the flow was set to 3.45 μL/min (5 mL/day). These input flow rates translate to approximately 1.725 μL/min (2.5 mL/day), respectively, of collectable fluid when accounting for evaporation under our specific laboratory conditions. This flow rate is very similar to physiological conditions (between 0.95 and 1.55 μL/min). As a result of the low flow rate, 50 μL samples were collected directly from the eyepieces. The low flow condition was tested with both blink and no-blink conditions.

Statistics

Statistical analysis was performed using Statistica 8 software (StatSoft, Tulsa, OK). All data are reported as mean ± standard deviation, unless otherwise stated. Repeated measures analysis of variance (RM-ANOVA) was performed to determine the differences across various time-points and lenses. Two-way ANOVA was performed to determine differences across testing groups. Post hoc Tukey multiple comparison tests were used when necessary. In all cases, statistical significance was considered significant for a p value of <0.05. Graphs were plotted using GraphPad Prism version 7.0 (GraphPad Software, La Jolla, CA).

RESULTS

As shown in Figure 2, nefficon A lenses containing PVA turn green-black when exposed to the solution of iodine-borate. This color change is indicative for the presence of PVA.
Etafun A turned a reddish orange and omaficon A turned orange. The color change in etaficon A is because of the presence of polyvinyl pyrrolidone (PVP) complexing with iodine.\(^{8,26}\) The iodine-borate solution is an orange color.

The total amount of PVA from the blister pack for nelicon A, shown in Table II, was 409.5 ± 56.7 μg, respectively (\(p < 0.001\)). The total amount of extractable PVA for nelicon A was 41.6 ± 9.6 μg/lens. Etafun A and omaficon A were rinsed in PBS and incubated in a solution of 1.8 mg/mL of PVA. The extractable PVA from these lenses were 14.7 ± 3.5 μg/lens (Table II) for etaficon A and 17.8 ± 5.6 μg/lens for omaficon A (Table II). The amount of extractable PVA for nelicon A was significantly higher than etaficon A and omaficon B (\(p < 0.001\)). There were no differences in the amount of PVA extracted from nelicon A after extraction times of 1 min, 24 h, or 48 h (\(p > 0.05\)).

The release of PVA from the CLs is summarized in Table III. Nelficon A significantly released more PVA than etaficon A and omaficon A incubated with PVA at the 0.5 and 1.5 h time points in both PBS and Milli-Q water (Fig. 3). All lenses had similar PVA release after the 4.5 h time-point. The release of PVA in PBS was higher than Milli-Q water for nelicon A (\(p < 0.05\)). The release of PVA was higher in Milli-Q water than PBS for omaficon A (\(p < 0.05\)), and there was no differences for etaficon A (\(p > 0.05\)).

Figure 4 shows the release of PVA over time in PBS under different blink conditions and flow rates for nelicon A. There was no statistical significance between the release profiles of PVA between the blink and no-blink conditions (\(p > 0.05\)). In addition, there were no differences in the PVA release profiles between the different flow rates in either the blink condition or no-blink condition (\(p > 0.05\)).

**DISCUSSION**

Both etaficon A and omaficon A inherently do not contain any PVA. To compare the release of PVA from these daily disposable hydrogel lenses with that from nelicon A, they were incubated in a PBS solution containing PVA to "load" the lenses with PVA. This solution had approximately four to five times more PVA than the blister pack for nelicon A. Despite this, the amount of inherently extractable PVA for nelicon A (41.6 ± 9.6 μg/lens) was significantly higher than both etaficon A (14.7 ± 3.5 μg/lens) and omaficon A (17.8 ± 5.6 μg/lens). These results clearly demonstrate that the nelicon A material does indeed deliver a significant level of PVA from the lens material, and that that level was greater than that which was achieved by merely "passively" loading hydrogel lenses even at a higher PVA concentration.

For nelicon A, the lenses were also extracted after 1 min and 24 h to compare the data with the 48 h extraction. The rationale behind the different extraction time points was to evaluate whether more PVA could be extracted from the lens over time. However, there were no differences in the amount of PVA extracted from the nelicon A lenses at any of the three time points (see Table II), with between 38 and 53 μg/lens being extracted (\(p > 0.05\)). Nelicon A lenses are synthesized from PVA, and so there could potentially be non-cross-linked PVA within the bulk of the lens material. PVA could also be added in excess during the manufacturing process. Previous studies hypothesized that these non cross-linked PVA molecules within the CL bulk could leach out over time, to provide sustained release of PVA from the lens.\(^{8,10}\)

The release of PVA from etaficon A, omaficon A, and nelicon A was investigated in both PBS and Milli-Q water using the OcuFlow platform. The release of PVA for all tested lens types and conditions followed a burst release within the first 4.5 h and plateaued thereafter. After 4.5 h, the amount of released PVA was similar between all lenses and conditions. For the OcuFlow release studies, nelicon A released significantly higher amounts of PVA at 0.5 and 1.5 h compared to etaficon A and omaficon A. These results are in agreement with the methanol extraction studies, where nelicon A had the highest amount of extractable PVA. There are two notable differences with the data in the current study and that previously published.\(^{16}\) The first relates to the burst release of PVA observed in the current study, the lenses with PVA.

---

**TABLE II. Total Amount of PVA in Blister pack (n = 3) and Total Amount of Extractable PVA From the lens after 48 h (n = 6) for etaficon A, omaficon A, and nelicon A**

| Total PVA in blister pack (μg) | etaficon A | omaficon A | nelicon A |
|-------------------------------|------------|------------|----------|
| PBS                           | 409.5 ± 56.7 | -          | -        |
| PVA (MW = 18 kDa) in 1 mL incubation solution (μg) | 1800 | 1800 | - |
| PVA extracted after 48 h (μg/lens) | 14.7 ± 3.5 | 17.8 ± 5.6 | 41.6 ± 9.6 |
| PVA extracted after 24 h (μg/lens) | 38.0 ± 16.0 | - | - |
| PVA extracted after 1 min (μg/lens) | 53.5 ± 10.1 | - | - |

**TABLE III. PVA Released From etaficon A, omaficon A, and nelicon A (μg) in PBS versus Milli-Q water (mean ± SD) n = 6**

| Time (h) | PBS | MilliQ | PBS | MilliQ | PBS | MilliQ |
|----------|-----|--------|-----|--------|-----|--------|
| 0.5      | 5.1 ± 2.7 | 6.7 ± 3.3 | 2.7 ± 2.6 | 4.6 ± 2.0 | 31.9 ± 11.5 | 16.9 ± 6.0 |
| 1.5      | 1.4 ± 0.8 | 1.6 ± 0.9 | 1.2 ± 1.7 | 1.8 ± 0.3 | 5.6 ± 2.2 | 4.2 ± 2.3 |
| 4.5      | 0.5 ± 0.2 | 0.2 ± 0.2 | 0.3 ± 0.6 | 1.5 ± 0.3 | 0.3 ± 0.1 | 0.0 ± 0.0 |
| 8.5      | 0.2 ± 0.1 | 0.4 ± 0.5 | 0.2 ± 0.4 | 0.1 ± 0.1 | 0.3 ± 0.1 | 0.1 ± 0.2 |
| 12.5     | 0.1 ± 0.1 | 0.0 ± 0.3 | 0.0 ± 0.1 | 0.0 ± 0.0 | 0.3 ± 0.0 | 0.0 ± 0.0 |
| 23.5     | 0.0 ± 0.1 | 0.4 ± 0.5 | 0.0 ± 0.1 | 0.0 ± 0.2 | 0.2 ± 0.0 | 0.0 ± 0.0 |
which was not reported in the previous study. The second difference is the time it took the lens to equilibrate in the previous work, which occurred approximately after 20 h. For the current study, the equilibrium was reached much faster, after 4.5 h for both the standard OcuFlow flow rate of 10 mL/day (6.9 μL/min) and a slower flow rate at 5 mL/day (3.45 μL/min). The faster flow rate in the current study compared to the 5 mL static incubation volume, or the 100 μL/h exchange rate previously used, could result in the observed differences in equilibration time.

We initially hypothesized that the differences in rate between these two studies could be due to the continuous rubbing mechanism from the OcuFlow platform, which could accelerate the release of PVA. As a blink activation is reported to be necessary to force PVA release from the lens and too much force could hypothetically accelerate PVA release. However, there were no differences in the amount of PVA released in the blink and no-blink condition using the OcuFlow, appearing to remove this as being a potential source of the differences in the data derived. These results suggest that the blink rate and/or force from the OcuFlow device did not have any significant effect on the release kinetics of PVA from nelfilcon A.

The release of PVA in PBS was higher than in Milli-Q water (p < 0.05) for nelfilcon A, despite the lenses swelling more in Milli-Q water than PBS. The mechanisms underlying the higher release in PBS for nelfilcon A are not clear. We hypothesize that it could be because of the interactions of the phosphate ions with the hydroxyl groups of PVA, which helps stabilize the molecule in aqueous solution, and therefore facilitates its release from the lens. A previous study has reported degradation of PVA in PBS from hydrolytic cleavage of hydrogen bonding among hydroxyl groups of PVA chains. The different lens preparation step, rinsing with PBS versus MilliQ, may also play a role.

The results from the current study suggest that PVA release, from the PVA-loaded omafilcon A and etafilcon A materials and the PVA-based nelfilcon A material, follows a typical burst release-plateau profile. These kinetics are in agreement with typical observations for the majority of drug delivery studies with commercial CLs. Although minute quantities of PVA leaving the lens materials were still detected after 4.5 h, the clinical significance for such small amounts of PVA release warrants further investigation. Based on the results, the clinical effect of PVA would be most apparent in the first 1.5–4.5 h. That being said, “drug delivery” with CLs is unique because the lens can entrap the released compound in the posterior lens tear film, holding it against the cornea. This area is shielded from the typical ocular removal mechanisms such as tear dilution and blinking, that remove drugs from the ocular surface. Consequently, the PVA released and entrapped between the lens and the cornea could remain longer on the ocular surface than expected. However, this would not occur over the front surface of the lens, in which it would act as a lubricant between the lens and the under surface of the eyelid, potentially reducing the frictional force between the lid and lens. Furthermore, this lubricating effect may not be long lasting with PVA, as shown by a previous in vitro study examining wear time and coefficient of friction (CoF). The CoF of nelfilcon A increased significantly after an in vitro aging process that simulated in vivo lens wear.

One further point to consider is that the values reported in the current study for the amount of wetting agent released are estimates of actual concentrations, as the standard curves used to derive these values were generated using commercially available versions of PVA. The assumption is that the molecular weights of PVA are reflective of the actual wetting agents found in the nelfilcon A blister packs. The actual molecular weight of PVA in the current commercial nelfilcon A lenses and in its blister pack is proprietary. Different molecular weights of PVA will have different uptake and release profiles from lenses.

FIGURE 3. Release of PVA (μg/lens) from contact lenses in (A) PBS and (B) Milli-Q water over 24 h (mean ± SD) n = 6.

FIGURE 4. Release of PVA (μg/lens) from nelfilcon A in PBS under different blink conditions and slower flow rate over 24 h.
To compensate for evaporation over the course of the sampling time, the input flow rate for the OcuFlow was set at 6.9 μL/min to collect enough sample for analysis at each time point. As elution of compounds from CLs is affected by tear flow rate,21 a faster flow rate will inevitably lead to a faster burst release. However, while the tear flow-rate in vivo will be slower, there are other components not simulated on the OcuFlow (such as faster blinking rates35 and exposure to corneal and conjunctival cells) that may increase elution of the wetting agents from the CLs.36

CONCLUSION
The purpose of the study was to evaluate the release of PVA from commercial CLs using a novel in vitro blink platform. Various conditions were tested, including different rinsing media, flow rates, and blink conditions. There were no differences in the release kinetics for different flow rates or blink conditions. For all tested conditions, burst release was observed within the first 1.5 h, which plateaued rapidly after 4.5 h. The PVA-based nelfilon A lenses released more PVA than PVA-loaded etafilcon A and omafilcon A. The results from the current study suggest that releasable PVA from nelfilon A is loosely bound on the surface or subsurface of the lens.

CONFLICT OF INTEREST
The authors Riederer, Lau, and Lorenz are employees of [J]. Jones and Subbaraman have received research support or lectureship honoraria from the following companies: Advanced Vision Research, Alcon, Allergan, Contamac, CooperVision, Essilor, GL Chemtec, Inflamex Research, [J] Vision, Menicon, Nature’s Way, Novartis, Ocular Dynamics, Oculus, Safilens, Santen, Shire, TearLab, TearScience. Jones is also a consultant and/or serves on an advisory board for Alcon, CooperVision, [J] Vision, Novartis and Ophthece.

REFERENCES
1. Dumbleton K, Caffery B, Dogru M, Hickson-Curran S, Kern J, Kojima T, Morgan PB, Purslow C, Robertson DM, Nelson JD, members of the TiWoCLD. The TFOS international workshop on contact lens discomfort: Report of the subcommittee on epidemiology. Invest OphthalmoVit Sci 2013;54:TFOS20–TFOS36.
2. Rumpakis J. New data on contact lens dropouts: An international perspective. Rev Optom 2010;1:37–42.
3. Young G, Veys J, Pritchard N, Coleman S. A multi-centre study of lapsed contact lens wearers. Ophthalmic Physiol Opt. 2002;22:516–527.
4. Dumbleton K, Woods CA, Jones LW, Fonn D. The impact of contemporary contact lenses on contact lens discontinuation. Eye Contact Lens 2013;39:93–99.
5. Pritchard N, Fonn D, Brazeau D. Discontinuation of contact lens wear: A survey. Int Contact Lens Clin 1999;26:157–162.
6. Nichols JJ, Willcox MD, Bron AJ, Belmonte C, Ciolfi MB, Craig JP, Dogru M, Fouks GN, Jones L, Nelson JD, Nichols KK, Purslow C, Schauberg DA, Stapleton F, Sullivan DA, members of the TiWoCLD. The TFOS international workshop on contact lens discomfort: Executive summary. Invest OphthalmoVit Sci 2013;54:TFOS7–TFOS13.
7. Peterson RC, Woldsohn JS, Nick J, Winterton L, Lally J. Clinical performance of daily disposable soft contact lenses using sustained release technology. Cont. Lens Anterior Eye 2006;29:127–134.
8. Ross G. Ocular Biotribology and Contact Lens Lubrication Mechanisms. Birmingham, UK: Aston University; 2009.
9. Walker J, Young G, Hunt C, Henderson T, Multi-Centre evaluation of two daily disposable contact lenses. Cont Lens Anterior Eye 2007;30:125–133.
10. Pruitt J, Lindley K, Winterton L. Triple-action moisturisers for increased comfort in daily disposable lenses. Optician 2007;234:27–28.
11. White CJ, McBride MK, Pate KM, Tieppo A, Byrne ME. Extended release of high molecular weight hydroxypropyl methylcellulose from molecularly imprinted, extended wear silicone hydrogel contact lenses. Biomaterials 2011;32:5698–5705.
12. Maulvi FA, Soni TG, Shah DO. Extended release of hyaluronic acid from hydrogel contact lenses for dry eye syndrome. J Biomater Sci Polym Ed 2015;26:1035–1050.
13. Pitt WG, Zhao Y, Jack DR, Perez KX, Jones PW, Marelli R, Nelson JL, Pruitt JD. Extended elution of phospholipid from silicone hydrogel contact lenses. J Biomater Sci Polym Ed. 2015;26:224–234.
14. White CJ, DiPasquale SA, Byrne ME. Controlled release of multiple therapeutics from silicone hydrogel contact lenses. Optom Vis Sci. 2016;93:377–386.
15. Mahomed A, Tighe B. Contact lenses and comfort enhancers: in vivo and in vitro. Poster presented at the BLCA Conference, June 3-6, 2004, Brighton UK. 2004.
16. Winterton LC, Lally JM, Sentell KB, Chapoy LL. The elution of poly (vinyl alcohol) from a contact lens: The realization of a time release moisturizing agent/artificial tear. J Biomed Mater Res B Appl Biomater. 2007;80:424–432.
17. Zerfa M, Brooks BW. Experimental investigation of PVA adsorption at the vinyl chloride/water interface in monomer suspensions. Colloids Surf A Physicochem Eng Asp. 1998;132:267–273.
18. Procházková L, Rodríguez-Muñoz Y, Procházka J, Wanner J. Simple spectrophotometric method for determination of polyvinylalcohol in different types of wastewater. Int J Environ Anal Chem 2013;94:399–410.
19. Mishima S, Gasset A, Klyce SD Jr, Baum JL. Determination of tear volume and tear flow. Invest OphthalmoVit Sci 1966;5:264–276.
20. Furukawa RE, Poole KA. Changes in tear flow accompanying aging. Am J Ophthalmol. 1978;55:69–74.
21. Baijegrowicz M, Phan CM, Subbaraman LN, Jones L. Release of ciprofloxacin and moxifloxacin from daily disposable contact lenses from an in vitro eye model. Invest OphthalmoVit Sci 2015;56:2234–2242.
22. Phan CM, Baijegrowicz M, Gao H, Subbaraman LN, Jones LW. Release of fluconazole from contact lenses using a novel in vitro eye model. Optom Vis Sci 2016;93:387–394.
23. Qiao H, Phan CM, Walther H, Subbaraman LN, Jones L. Depth profile assessment of the early phase deposition of lysosome on soft contact lens materials using a novel in vitro eye model. Eye Contact Lens 2017;1:doi:10.1167/iovs.2016-16000000000397.
24. Walther H, Phan C-M, Subbaraman LN, Jones L. Differential deposition of fluorescently tagged cholesterol on commercial contact lenses using a novel in vitro eye model. Trans Vis Sci Technol 2018;7:18.
25. Herrmann W, Haehnel W. Über den olyn-vinyllalkohol. Ber Dtsch Chem Ges 1927;60:1658–1663.
26. Arena MP, Porter MD, Fritz JS. Rapid, specific determination of iodine and iodide by combined solid-phase extraction/diffuse reflectance spectroscopy. Anal Chem 2002;74:185–190.
27. Phan CM, Subbaraman L, Liu S, Gu F, Jones L. In vitro uptake and release of natamycin in micro-PLA nanoparticles from model contact lens materials. J Biomater Sci Polym Ed 2014;25:18–31.
28. Kenawy E, Kamoun E, Elidin M, El-Meligy M. Physically crosslinked poly (vinyl alcohol)-hydroxyethyl starch blend hydrogel membranes: Synthesis and characterization for biomedical applications. Arab J Chem 2014;7:372–380.
29. Soluri A, Hui A, Jones L. Delivery of ketotifen fumarate by commercial contact lens materials. Optom Vis Sci 2012;89:1140–1149.
30. Phan CM, Subbaraman LN, Jones L. In vitro uptake and release of natamycin from conventional and silicone hydrogel contact lens materials. Eye Contact Lens 2013;39:162–168.
31. Hui A, Boone A, Jones L. Uptake and release of ciprofloxacin-HCl from conventional and silicone hydrogel contact lens materials. Eye Contact Lens 2008;34:266–271.
32. Boone A, Hui A, Jones L. Uptake and release of dexamethasone phosphate from silicone hydrogel and group I, II, and IV hydrogel contact lenses. Eye Contact Lens 2009;35:260–267.

33. Chrai SS, Makoid MC, Eriksen SP, Robinson JR. Drop size and initial dosing frequency problems of topically applied ophthalmic drugs. J Pharm Sci. 1974;63:333–338.

34. Sterner O, Aeschlimann R, Zurcher S, Osborn Lorenz K, Kakkassery J, Spencer ND, Tosatti SG. Friction measurements on contact lenses in a physiologically relevant environment: effect of testing conditions on friction. Invest. Ophthalmol. Vis. Sci. 2016;57:5383–5392.

35. Sforza C, Rango M, Galante D, Bresolin N, Ferrario VF. Spontaneous blinking in healthy persons: An optoelectronic study of eyelid motion. Ophthalmic Physiol Opt 2008;28:345–353.

36. Mohammadi S, Jones L, Gorbet M. Extended latanoprost release from commercial contact lenses: in vitro studies using corneal models. PLoS One 2014;9:e106653.